| Business Summary | | Affymetrix,
Inc.
is
engaged
in
the
field
of
DNA
chip
technology.
Affymetrix
has
developed
and
intends
to
establish
its
GeneChip
system
and
related
microarray
technologies
as
platforms
for
acquiring,
analyzing
and
managing
genetic
information.
The
GeneChip
system
consists
of
disposable
DNA
probe
arrays
containing
gene
sequences
on
a
chip,
certain
reagents
for
use
with
the
probe
arrays,
a
scanner
and
other
instruments
to
process
the
probe
arrays
and
software
to
analyze
and
manage
genetic
information
from
the
probe
arrays.
Related
microarray
technology
offered
includes
instrumentation,
software
and
licenses
for
fabricating,
scanning,
collecting
and
analyzing
results
from
low-density
microarrays.
The
Company
sells
its
products
directly
to
pharmaceutical
and
biotechnology
companies,
academic
research
centers,
private
foundations
and
clinical
reference
laboratories
in
the
United
States
and
Europe.
The
Company
also
sells
its
products
through
certain
distributors,
principally
in
Japan. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | AFFX
develops
GeneChip
based
products
and
related
technology
for
the
acquisition,
analysis
and
management
of
complex
genetic
data.
The
Company
sells
its
products
to
pharmaceutical
and
biotechnology
companies.
For
the
six
months
ended
6/30/01,
revenues
rose
22%
to
$104.4
million.
Net
loss
rose
61%
to
$19.9
million.
Revenues
reflect
increased
sales
of
GeneChip(R)
probe
arrays.
Higher
loss
suffered
from
$9.4
million
in
amortization
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Stephen Fodor, Ph.D., 47 CEO
and Chairman | $620K | $6.7M | Susan Siegel, 40 Pres | -- | 5.4M | John Diekman, Ph.D., 58 Vice
Chairman | -- | -- | Gregory Schiffman CFO,
VP | -- | -- | Barbara Caulfield Exec.
VP, Gen. Counsel | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|